BERGEN, Norway, April 9, 2014 /PRNewswire via COMTEX/ -- BERGEN, Norway, April 9, 2014 /PRNewswire/ --
or the "Company"), an oncology biopharmaceutical company, announces that results from its successful Phase Ia clinical study for lead compound, BGB324, was presented at the American Association of Cancer Research annual conference, which took place on April 5-9, 2014.
Help employers find you! Check out all the jobs and post your resume.
